用于前列腺癌初始分期的分子影像学。
Molecular Imaging for Primary Staging of Prostate Cancer.
机构信息
Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Germany; Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Germany; Nuclear Medicine Division, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
出版信息
Semin Nucl Med. 2019 Jul;49(4):271-279. doi: 10.1053/j.semnuclmed.2019.02.004. Epub 2019 Mar 20.
According to SEER Cancer Statistics Review there are around 165,000 new prostate cancer cases estimated in 2018 accounting for 9.5% of all newly diagnosed cancers. Accurate staging of primary prostate cancer is important for therapy selection (local vs systemic). Recent developments in molecular imaging may significantly impact staging procedures and management. Accordingly, this article addresses the current clinical standard, discusses the areas of unmet clinical need for imaging and then summarizes the most commonlyused molecular imaging probes. Finally, the authors dare an outlook to the short-term future role of molecular imaging in primary staging of prostate cancer.
据 SEER 癌症统计评论估计，2018 年有大约 165000 例新的前列腺癌病例，占所有新诊断癌症的 9.5%。准确分期原发性前列腺癌对于治疗选择（局部与全身）很重要。分子成像的最新进展可能会对分期程序和管理产生重大影响。因此，本文介绍了当前的临床标准，讨论了成像领域未满足的临床需求，然后总结了最常用的分子成像探针。最后，作者大胆展望了分子成像在前列腺癌初始分期中的短期未来作用。
Zotero 插件